Literature DB >> 11673790

The other, forgotten genome: mitochondrial DNA and mental disorders.

T Kato1.   

Abstract

This paper summarizes recent research on mitochondrial DNA (mtDNA)--which might be described as the "other, forgotten genome". Recent studies suggest the possible pathophysiological significance of mtDNA in schizophrenia and neurodegenerative and mood disorders. Decreased activity of the mitochondrial electron transport chain has been implicated in both Parkinson's and Alzheimer's disease and while age-related accumulation of mtDNA deletions has been suggested as a possible cause, there is no concrete evidence that particular mtDNA polymorphisms are responsible. In schizophrenia, the activity and/or mRNA expression of complex IV are involved, but the direction of the alteration is not the same and there is no evidence linking schizophrenia with mtDNA. In bipolar disorder, there is some evidence of parent-of-origin effects and association with mtDNA polymorphisms but further investigation is needed to elucidate the role of mtDNA in mental disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673790     DOI: 10.1038/sj.mp.4000926

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  17 in total

1.  Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors:  Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal:  Antioxid Redox Signal       Date:  2019-02-01       Impact factor: 8.401

Review 2.  Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications.

Authors:  Tadafumi Kato
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  A Genome-Wide Search for Bipolar Disorder Risk Loci Modified by Mitochondrial Genome Variation.

Authors:  Euijung Ryu; Malik Nassan; Gregory D Jenkins; Sebastian M Armasu; Ana Andreazza; Susan L McElroy; Marquis P Vawter; Mark A Frye; Joanna M Biernacka
Journal:  Mol Neuropsychiatry       Date:  2017-10-28

4.  Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression.

Authors:  Edana Cassol; Vikas Misra; Susan Morgello; Gregory D Kirk; Shruti H Mehta; Dana Gabuzda
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

5.  Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.

Authors:  Ahmed T Ahmed; Siamak MahmoudianDehkordi; Sudeepa Bhattacharyya; Matthias Arnold; Duan Liu; Drew Neavin; M Arthur Moseley; J Will Thompson; Lisa St John Williams; Gregory Louie; Michelle K Skime; Liewei Wang; Patricio Riva-Posse; William M McDonald; William V Bobo; W Edward Craighead; Ranga Krishnan; Richard M Weinshilboum; Boadie W Dunlop; David S Millington; A John Rush; Mark A Frye; Rima Kaddurah-Daouk
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

Review 6.  Impaired mitochondrial function in psychiatric disorders.

Authors:  Husseini Manji; Tadafumi Kato; Nicholas A Di Prospero; Seth Ness; M Flint Beal; Michael Krams; Guang Chen
Journal:  Nat Rev Neurosci       Date:  2012-04-18       Impact factor: 34.870

Review 7.  Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.

Authors:  Kurt F Hauser; Pamela E Knapp
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

Review 8.  Mitochondrial involvement in psychiatric disorders.

Authors:  Ling Shao; Maureen V Martin; Stanley J Watson; Alan Schatzberg; Huda Akil; Richard M Myers; Edward G Jones; William E Bunney; Marquis P Vawter
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

Review 9.  Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: how important is BDNF?

Authors:  A Markham; R Bains; P Franklin; M Spedding
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

10.  Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia.

Authors:  Kazuya Iwamoto; Miki Bundo; Shinsuke Washizuka; Chihiro Kakiuchi; Tadafumi Kato
Journal:  J Hum Genet       Date:  2004       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.